A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer.

Trial Profile

A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Acronyms Her+XELOX
  • Most Recent Events

    • 28 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 Nov 2018.
    • 28 Jun 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2018.
    • 13 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top